Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti-interleukin-1beta monoclonal antibody. METHODS: We performed a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS. In part 1, 35 patients received 150 mg of canakinumab subcutaneously. Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 weeks for up to 24 weeks. After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab. We evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA). RESULTS: In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab. Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission. Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P<0.001). At the end of part 2, median CRP and SAA values were normal (<10 mg per liter for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P<0.001 and P=0.002, respectively). Of the 31 patients, 28 (90%) completed part 3 in remission. In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo. CONCLUSIONS: Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, IL-1RA-blocking Ab (anakinra) and IL-1β-blocking Ab (canakinumab) are already FDA approved as anti-inflammatory biologics for the treatment of rheumatoid arthritis (130) and NLRP3-inflammasome-mediated cryopyrin-associated periodic syndrome (CAPS) (131), respectively.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [131]
Citations
Cites
Natural History and Outcome in Systemic AA Amyloidosis
Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,032
Self-citationSpectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. F. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 744
Self-citationHoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577 · cited 2×
“Viral infection 0 2 (13) 0 0 Headache 0 2 (13) 0 3 ( 10 )”
URTICARIA, DEAFNESS, AND AMYLOIDOSIS: A NEW HEREDO-FAMILIAL SYNDROME
(1962) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a066967 · Cited by 372
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Self-citationPrimer: inflammasomes and interleukin 1β in inflammatory disorders
Church, L. D., Cook, G. P., & McDermott, M. F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0681 · Cited by 309
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Bijlsma, J. W. J., Dougados, M., Emery, P., Keystone, E. C., Klareskog, L., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044941 · Cited by 225
Leslie, K. S., Lachmann, H. J., Bruning, E., McGrath, J. A., Bybee, A., Gallimore, J. R., Roberts, P. F., Woo, P., Grattan, C. E., & Hawkins, P. N. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.12.1591 · Cited by 186 · cited 13×
“Rhinitis 4 (11) 1 (7) 2 (12) 0 Bronchitis 3 (9) 1 ( 7 ) 1 (6) 0”
InfluentialSelf-citationAlten, R., Gram, H., Joosten, L. A., Berg, W. B. V. D., Sieper, J., Wassenberg, S., Burmester, G., van Riel, P., Diaz-Lorente, M., Bruin, G. J., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2438 · Cited by 170
The many worlds of reducing interleukin‐1
Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21107 · Cited by 104
Research works printed but not linked: 5
- Muckle TJ, 1962, Q J Med, 31, 235
- Lachmann HJ, 2008, Clin Exp Rheumatol, 26, 181
- Kuemmerle-Deschner JB, 2008, Clin Exp Rheumatol, 26, 180
- Kummerle-Deschner J, 2008, Ann Rheum Dis, 67, 104
- Maier J, 2008, J Rheumatol, 35, 939
Cited by
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
“Mechanisms by which inflammasome activation and elevated IL-1 b may drive the progression from obesity to T2D are reviewed elsewhere in detail (Schroder et al., 2010).”
InfluentialCaspase Functions in Cell Death and Disease
McIlwain, D. R., Berger, T., & Mak, T. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008656 · Cited by 2,594
“Newer agents include monoclonal antibodies (mAbs) directed against IL-1b (canakinumab) (Alten et al. 2008; Church and McDermott 2009; Lachmann et al. 2009a), and IL-1Trap, a decoy receptor with high affinity for IL-1 (Kalliolias and Liossis 2008).”
BackgroundCytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.05.014 · Cited by 2,162
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
The IL-1 family: regulators of immunity
Sims, J. E., & Smith, D. E. (2010) · Nature Reviews Immunology · doi:10.1038/nri2691 · Cited by 1,418
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
“Canakinumab is approved for the treatment of a group of autoinflammatory diseases now termed cryopyrin-associated periodic syndromes (CAPS) that includes familial cold autoinflammatory syndrome, Mucle-Wells syndrome, and Neonatal Onset Multiinflammatory Disease (see Essay by D.L. Kastner et al. in this issue; Lachmann…”
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Wechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01274-x · Cited by 994
Self-citationRidker, P. M. (2016) · Circulation Research · doi:10.1161/circresaha.115.306656 · Cited by 1,002
Weber, A., Wasiliew, P., & Kracht, M. (2010) · Science Signaling · doi:10.1126/scisignal.3105cm1 · Cited by 962
Caspases in Cell Death, Inflammation, and Pyroptosis
Kesavardhana, S., Malireddi, R. K. S., & Kanneganti, T.-D. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-073119-095439 · Cited by 923
Inflammasomes and Their Roles in Health and Disease
Lamkanfi, M., & Dixit, V. M. (2012) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101011-155745 · Cited by 935
“This is also illustrated by the successful application of IL-1 inhibitors in patients suffering from hereditary autoinflammatory disorders, gouty arthritis, and type II diabetes (Lachmann et al. 2009, Lamkanfi et al. 2011, Larsen et al. 2007).”
BackgroundNLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
Grebe, A., Hoss, F., & Latz, E. (2018) · Circulation Research · doi:10.1161/circresaha.118.311362 · Cited by 926
IL-1 pathways in inflammation and human diseases
Gabay, C., Lamacchia, C., & Palmer, G. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.4 · Cited by 897
“as did a clinical trial of treatment with the anti-IL-1β antibody canakinumab (150 mg every 8 weeks, administered subcutaneously)”
MethodPathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
“Multiple clinical observations support the concept that a net balance of inflammatory activity influenced by relative levels of IL-1 and IL-1Ra contributes to human disease.26-29 First, specific amino acid mutations altering the NLRP3 inflammasome can increase secretion of IL-1β and result in a group of autoinflammato…”
BackgroundA clinical perspective of IL‐1β as the gatekeeper of inflammation
Dinarello, C. A. (2011) · European Journal of Immunology · doi:10.1002/eji.201141550 · Cited by 775
Baroja-Mazo, A., Martín-Sánchez, F., Gomez, A. I., Martínez, C. M., Amores-Iniesta, J., Compan, V., Barberà-Cremades, M., Yagüe, J., Ruiz-Ortiz, E., Antón, J., et al. (2014) · Nature Immunology · doi:10.1038/ni.2919 · Cited by 790
Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., & Rouis, M. (2015) · Redox Biology · doi:10.1016/j.redox.2015.01.008 · Cited by 732
Canna, S. W., de Jesus, A. A., Gouni, S., Brooks, S. R., Marrero, B., Liu, Y., DiMattia, M. A., Zaal, K. J. M., Sanchez, G. A. M., Kim, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.3089 · Cited by 740
De Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H., Braga, M., Di Carlo, V., Doglioni, C., & Protti, M. P. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101876 · Cited by 695
“Clinical grade anti–IL-1 Abs are available to treat autoimmune and autoinflammatory diseases (van den Berg, 2000; Atzeni and Sarzi-Puttini, 2009; Lachmann et al., 2009) and, recently, treatment with an IL-1 inhibitor in patients with smoldering or indolent multiple myeloma at risk of progression to…”
BackgroundTwo Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Ruperto, N., Brunner, H. I., Quartier, P., Constantin, T., Wulffraat, N., Horneff, G., Brik, R., McCann, L., Kasapcopur, O., Rutkowska-Sak, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205099 · Cited by 713
“Abdominal pain 3 (7) 1 (2) 26 (15) 8 (16) 6 (12)”
Self-citationAtherosclerosis and inflammation: overview and updates
Geovanini, G. R., & Libby, P. (2018) · Clinical Science · doi:10.1042/cs20180306 · Cited by 703
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
Libby, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.028 · Cited by 619
“inflammatory diseases mediated by IL-1b, including Muckle-Wells syndrome (71) and rarer forms of juvenile inflammatory arthritis (72) and common diseases such as acute gouty arthritis (73).”
Chronic Inflammation in Cancer Development
Multhoff, G., Molls, M., & Radons, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00098 · Cited by 576
Marchetti, C., Swartzwelter, B., Gamboni, F., Neff, C. P., Richter, K., Azam, T., Carta, S., Tengesdal, I., Nemkov, T., D’Alessandro, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716095115 · Cited by 574
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Ridker, P. M., Howard, C. P., Walter, V., Everett, B., Libby, P., Hensen, J., & Thuren, T. (2012) · Circulation · doi:10.1161/circulationaha.112.122556 · Cited by 530
Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation
Romberg, N., Al Moussawi, K., Nelson-Williams, C., Stiegler, A. L., Loring, E., Choi, M., Overton, J., Meffre, E., Khokha, M. K., Huttner, A. J., et al. (2014) · Nature Genetics · doi:10.1038/ng.3066 · Cited by 517
Autoinflammatory Disease Reloaded: A Clinical Perspective
Kastner, D. L., Aksentijevich, I., & Goldbach-Mansky, R. (2010) · Cell · doi:10.1016/j.cell.2010.03.002 · Cited by 487
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes
De Benedetti, F., Gattorno, M., Anton, J., Ben-Chetrit, E., Frenkel, J., Hoffman, H. M., Koné-Paut, I., Lachmann, H. J., Ozen, S., Simon, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706314 · Cited by 486
Self-citationThe NLRP3 inflammasome: contributions to inflammation-related diseases
Chen, Y., Ye, X., Escames, G., Lei, W., Zhang, X., Li, M., Jing, T., Yao, Y., Qiu, Z., Wang, Z., et al. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00462-9 · Cited by 492
Palomo, J., Dietrich, D., Martin, P., Palmer, G., & Gabay, C. (2015) · Cytokine · doi:10.1016/j.cyto.2015.06.017 · Cited by 447
Emerging inflammasome effector mechanisms
Lamkanfi, M. (2011) · Nature Reviews Immunology · doi:10.1038/nri2936 · Cited by 434
“Thus, IL-1β and IL-18 are important inflammasome effector molecules, as illustrated by the marked response to therapy with IL-1 inhibitors found in patients with cryopyrinopathies, who have increased inflammasome activatio”
BackgroundThe NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Wang, L., & Hauenstein, A. V. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100889 · Cited by 426
Manthiram, K., Zhou, Q., Aksentijevich, I., & Kastner, D. L. (2017) · Nature Immunology · doi:10.1038/ni.3777 · Cited by 399
The NLRP3 inflammasome in health and disease: the good, the bad and the ugly
Menu, P., & Vince, J. E. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04440.x · Cited by 389
The IL-1 family of cytokines and receptors in rheumatic diseases
Dinarello, C. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0277-8 · Cited by 366
Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
Schett, G., McInnes, I. B., & Neurath, M. F. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1909094 · Cited by 355
Schlesinger, N., Alten, R. E., Bardin, T., Schumacher, H. R., Bloch, M., Gimona, A., Krammer, G., Murphy, V., Richard, D., & So, A. K. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200908 · Cited by 359
Role of IL-1β in type 2 diabetes
Dinarello, C. A., Donath, M. Y., & Mandrup-Poulsen, T. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32833bf6dc · Cited by 327
Pathogenesis of acute stroke and the role of inflammasomes
Fann, D. Y.-W., Lee, S.-Y., Manzanero, S., Chunduri, P., Sobey, C. G., & Arumugam, T. V. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.09.004 · Cited by 335
IL-1 Blockade in Autoinflammatory Syndromes
Jesus, A. A., & Goldbach-Mansky, R. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061512-150641 · Cited by 326
The role of inflammasomes in kidney disease
Komada, T., & Muruve, D. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0158-z · Cited by 304
So, A., De Meulemeester, M., Pikhlak, A., Yücel, A. E., Richard, D., Murphy, V., Arulmani, U., Sallstig, P., & Schlesinger, N. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27600 · Cited by 315
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Self-citationAnakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
Triacylglycerol synthesis enhances macrophage inflammatory function
Castoldi, A., Monteiro, L. B., van Teijlingen Bakker, N., Sanin, D. E., Rana, N., Corrado, M., Cameron, A. M., Hässler, F., Matsushita, M., Caputa, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17881-3 · Cited by 296
The Inflammasomes and Autoinflammatory Syndromes
Broderick, L., De Nardo, D., Franklin, B. S., Hoffman, H. M., & Latz, E. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040431 · Cited by 295
Okamoto, M., Liu, W., Luo, Y., Tanaka, A., Cai, X., Norris, D. A., Dinarello, C. A., & Fujita, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.064907 · Cited by 293
Drug Repurposing for Rare Diseases
Roessler, H. I., Knoers, N. V. A. M., van Haelst, M. M., & van Haaften, G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.01.003 · Cited by 269
Why not treat human cancer with interleukin-1 blockade?
Dinarello, C. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9229-0 · Cited by 277
“In healthy humans, daily constitutive production of IL-1β was calculated at 6 ng; in patients with cryopyrinassociated periodic syndromes (CAPS), a rare genetic disease due to IL-1β production was calculated at 31 ng/ day.”
BackgroundInfluentialRecommendations for the management of autoinflammatory diseases
ter Haar, N. M., Oswald, M., Jeyaratnam, J., Anton, J., Barron, K. S., Brogan, P. A., Cantarini, L., Galeotti, C., Grateau, G., Hentgen, V., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207546 · Cited by 278
Self-citationIL‐1: Discoveries, controversies and future directions
Dinarello, C. A. (2010) · European Journal of Immunology · doi:10.1002/eji.201040319 · Cited by 268
Dhimolea, E. (2010) · mAbs · doi:10.4161/mabs.2.1.10328 · Cited by 270
Averting inflammation by targeting the cytokine environment
Kopf, M., Bachmann, M. F., & Marsland, B. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2805 · Cited by 257
“; canakinumab (Ilaris; Novartis), a fully human IL-1β-specific mA”
BackgroundWinthrop, K. L., Mariette, X., Silva, J. T., Benamu, E., Calabrese, L. H., Dumusc, A., Smolen, J. S., Aguado, J. M., & Fernández-Ruiz, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.002 · Cited by 259
“Current evidence mostly derived from observational studies (prospective and retrospective), open-label studies and small-size RCTs [36-39].”
BackgroundLoop Between NLRP3 Inflammasome and Reactive Oxygen Species
Dominic, A., Le, N.-T., & Takahashi, M. (2022) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8257 · Cited by 242
Booshehri, L. M., & Hoffman, H. M. (2019) · Journal of Clinical Immunology · doi:10.1007/s10875-019-00638-z · Cited by 239
The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases
de Torre-Minguela, C., Mesa del Castillo, P., & Pelegrín, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00043 · Cited by 238
“It has shown a very rapid and sustained response with little side effects, mainly infections, with stabilization of the majority of sequelae and potential improvement in clinical manifestations such as sensory-neural hearing loss (190).”
BackgroundSchlesinger, N., Mysler, E., Lin, H.-Y., De Meulemeester, M., Rovensky, J., Arulmani, U., Balfour, A., Krammer, G., Sallstig, P., & So, A. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144063 · Cited by 244
Blockade of interleukin 1 in type 1 diabetes mellitus
Mandrup-Poulsen, T., Pickersgill, L., & Donath, M. Y. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.271 · Cited by 237
“Antibodies or soluble receptors that neutralize either IL-1β alone or both IL-1α and IL-1β have also been developed and have shown benefit to treat cryopyrin-associated periodic syndrome”
BackgroundNLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword
Hamarsheh, S., & Zeiser, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01444 · Cited by 230
“They continued their pioneering work in this field (15), which led to discovering the association of inflammasomes with CAPS (16), as well as gout and type 2 diabetes.”
BackgroundResultInfluentialInterleukin-1β and the Autoinflammatory Diseases
Dinarello, C. A. (2009) · New England Journal of Medicine · doi:10.1056/nejme0811014 · Cited by 226
Biologics for targeting inflammatory cytokines, clinical uses, and limitations
Rider, P., Carmi, Y., & Cohen, I. (2016) · International Journal of Cell Biology · doi:10.1155/2016/9259646 · Cited by 226
Mechanisms of uric acid crystal‐mediated autoinflammation
Martinon, F. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00860.x · Cited by 224
“In line with this idea, inhibition of IL-1b with an anti-IL-1b antibody restores normal production of IL-1b in patients with constitutive NALP3 ⁄ NLRP3 activation (124).”
BackgroundThe role of the NLRP3 inflammasome in gout
McDermott, M., Kingsbury, S., & Conaghan (2011) · Journal of Inflammation Research · doi:10.2147/jir.s11330 · Cited by 219
Kuemmerle-Deschner, J. B., Hachulla, E., Cartwright, R., Hawkins, P. N., Tran, T. A., Bader-Meunier, B., Hoyer, J., Gattorno, M., Gul, A., Smith, J., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.152728 · Cited by 222
Self-citationSibley, C. H., Plass, N., Snow, J., Wiggs, E. A., Brewer, C. C., King, K. A., Zalewski, C., Kim, H. J., Bishop, R., Hill, S., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34409 · Cited by 220
“Whether the rapid response to anakinra can also be attributed to its ability to block both IL-1α and IL-1β is currently not known; however, CAPS patients respond to treatment with specific IL-1β blockade (13).”
BackgroundUpdated insights into the molecular networks for NLRP3 inflammasome activation
Paik, S., Kim, J. K., Shin, H. J., Park, E.-J., Kim, I. S., & Jo, E.-K. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01284-9 · Cited by 180
“It is highly effective in treating CAPS, signi fi cantly improving patients ’ quality of life and reducing the risk of amyloidosis [402].”
Monogenic autoinflammatory diseases: Concept and clinical manifestations
Almeida de Jesus, A., & Goldbach-Mansky, R. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.03.016 · Cited by 212
NLRP3 Inflammasome Activation Induced by Engineered Nanomaterials
Sun, B., Wang, X., Ji, Z., Li, R., & Xia, T. (2013) · Small · doi:10.1002/smll.201201962 · Cited by 204
Chakraborty, A., Tannenbaum, S., Rordorf, C., Lowe, P. J., Floch, D., Gram, H., & Roy, S. (2012) · Clinical Pharmacokinetics · doi:10.2165/11599820-000000000-00000 · Cited by 199
“Except for the phase III trial in CAPS patients,([11]) the drug material from the NS0 cell line was used in all the clinical trials presented in the current review.”
BackgroundMethodInfluentialThe mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
Zhan, X., Li, Q., Xu, G., Xiao, X., & Bai, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1109938 · Cited by 181
“recombinant form of IL-1RA (Anakinra) (74), the anti-IL-1b monoclonal antibody (Canakinumab) (75), and the dimeric IL-1 receptor fusion protein (Rilonacept) (76).”
BackgroundRuperto, N., Quartier, P., Wulffraat, N., Woo, P., Ravelli, A., Mouy, R., Bader‐Meunier, B., Vastert, S. J., Noseda, E., D'Ambrosio, D., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33342 · Cited by 196
Self-citationInfectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E., Gedye, C., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 187
Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever: A Randomized Trial
Hashkes, P. J., Spalding, S. J., Giannini, E. H., Huang, B., Johnson, A., Park, G., Barron, K. S., Weisman, M. H., Pashinian, N., Reiff, A. O., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-8-201210160-00003 · Cited by 188
Targeting the NLRP3 inflammasome for inflammatory disease therapy
Cabral, J. E., Wu, A., Zhou, H., Pham, M. A., Lin, S., & McNulty, R. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.04.007 · Cited by 201
“Treatment showed symptom remission in the REMITTER trial (NCT01576367) [53], but was ineffective in NSCLC in the CANOPY-2 (NCT03626545) and CANOPY-A (NCT03447769) trials [54,55].”
How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1
Keyel, P. A. (2014) · Cytokine · doi:10.1016/j.cyto.2014.03.007 · Cited by 176
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting
Broderick, L., & Hoffman, H. M. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00797-1 · Cited by 171
Cuisset, L., Jeru, I., Dumont, B., Fabre, A., Cochet, E., Le Bozec, J., Delpech, M., Amselem, S., & Touitou, I. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.138420 · Cited by 173
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies
Cavalli, G., & Dinarello, C. A. (2015) · Rheumatology · doi:10.1093/rheumatology/kev269 · Cited by 171
NF-κB: master regulator of cellular responses in health and disease
Hoffmann, A., Cheng, G., & Baltimore, D. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00014-0 · Cited by 193
“Canakinumab (Ilaris), a human monoclonal antibody targeting IL-1β, preventing its binding to IL-1R and subsequent NF-κB activation, is approved for cryopyrin-associated periodic syndromes (CAPS) and gouty arthritis [162].”
Cytokine Circuits in Cardiovascular Disease
Williams, J. W., Huang, L.-H., & Randolph, G. J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.007 · Cited by 164
“, 2016) and cryopyrin-associated periodic syndrome (Lachmann et al., 2009).”
The Inflammasome in Myocardial Injury and Cardiac Remodeling
Toldo, S., Mezzaroma, E., Mauro, A. G., Salloum, F., Van Tassell, B. W., & Abbate, A. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5989 · Cited by 160
Piram, M., Koné-Paut, I., Lachmann, H. J., Frenkel, J., Ozen, S., Kuemmerle-Deschner, J., Stojanov, S., Simon, A., Finetti, M., Sormani, M. P., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203666 · Cited by 160
Self-citationThe future of drug development: advancing clinical trial design
Orloff, J., Douglas, F., Pinheiro, J., Levinson, S., Branson, M., Chaturvedi, P., Ette, E., Gallo, P., Hirsch, G., Mehta, C., et al. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3025 · Cited by 158
“The data derived from this modelling exercise allowed for selection of a dosing regimen that was investigated and confirmed in a Phase III tria”
Self-citationThe role of inflammasome-derived IL-1 in driving IL-17 responses
Mills, K. H. G., Dungan, L. S., Jones, S. A., & Harris, J. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012543 · Cited by 153
“It has already been demonstrated that anakinra, a recombinant form of the naturally occurring human IL-1Ra, is highly effective in treating several autoinflammatory disorders, including gout, CAPS, and DIRA [1, 88, 131].”
BackgroundInfluentialGiornale italiano di Dermatologia e Venereologia
Ribero, S., Quaglino, P., Sanlorenzo, M., Osella‐Abate, S., Marenco, F., Fierro, M. T., & Bernengo, M. G. (2012) · Institutional Research Information System University of Turin (University of Turin) · Cited by 155
Inflammasome and IL-1β-Mediated Disorders
Hoffman, H. M., & Wanderer, A. A. (2010) · Current Allergy and Asthma Reports · doi:10.1007/s11882-010-0109-z · Cited by 151
“responses and were subsequently approved by the US Food and Drug Administration under its orphan drug program [7, 8].”
BackgroundMethodDeregulated inflammasome signaling in disease
Lamkanfi, M., Walle, L. V., & Kanneganti, T. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01042.x · Cited by 155
“Similarly, the safety and efficacy of the human IL-1b neutralizing monoclonal antibody canakinumab (Ilaris, Novartis, Basel, Switzerland) and rilonacept (Arcalyst, Regeneron, Tarrytown, NY, USA), a fusion protein of the ligand-binding domains of human IL-1 receptor (IL-1R1) and IL-1 receptor accessory protein (IL-1RAc…”
BackgroundAlten, R., Gómez-Reino, J. J., Durez, P., Beaulieu, A. D., Sebba, A. I., Krammer, G., Preiss, R., Arulmani, U., Widmer, A., Gitton, X., et al. (2011) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-12-153 · Cited by 161
“This agent has recently been approved by the US Food and Drug Administration (FDA), by the European Medicines Agency, in Switzerland, and in other countries for the treatment of another IL-1beta-driven disease, cryopyrinassociated periodic syndrome, in which it has demonstrated significant and long-lasting efficacy […”
BackgroundSelf-citationStrategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space
Schwaid, A. G., & Spencer, K. B. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01307 · Cited by 160
Goldbach‐Mansky, R. T., & Kastner, D. L. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.016 · Cited by 172
Simonini, G., Xu, Z., Caputo, R., de Libero, C., Pagnini, I., Pascual, V., & Cimaz, R. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37776 · Cited by 152
“Canakinumab is an anti–IL-1 monoclonal antibody that is effective in the treatment of cryopyrinassociated periodic syndromes (7) and currently approved for that indication.”
BackgroundGoldbach‐Mansky, R. T. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04533.x · Cited by 155
Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases
Fenini, G., Contassot, E., & French, L. E. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00278 · Cited by 137
“In the third and final open-label part, all enrolled patients received Canakinumab and 97% sustained clinical and biochemical remission at the end of the study (ClinicalTrials.gov Identifier: NCT00465985) (Lachmann et al., 2009).”
Background
Metadata
- Authors
- Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N.
- Affiliations
- University College London (GB)
- Universitätsklinikum Tübingen (DE)
- University of California, San Francisco (US)
- Université de Lille (FR)
- Hôpital Necker-Enfants Malades (FR)
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-06-04
- Volume
- 360
- Issue
- 23
- Pages
- 2416-2425
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149374693
- Cited by
- 869
- References
- 19
- Citations by year
- 2026: 23 · 2025: 30 · 2024: 31 · 2023: 23 · 2022: 37 · 2021: 40 · 2020: 53 · 2019: 56 · 2018: 34 · 2017: 38 · 2016: 55 · 2015: 67 · 2014: 50 · 2013: 66 · 2012: 73
- FWCI
- 35.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- canakinumab, cryopyrin-associated periodic syndromes, IL-1β, interleukin-1 receptor antagonist, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, disease flares, C-reactive protein, serum amyloid A, infection risk, urosepsis, vertigo, treatment withdrawal
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Adolescent, Adult, Aged, Antibodies, Monoclonal, Carrier Proteins, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Familial Mediterranean Fever, Interleukin-1beta, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.